Tramadol Hydrochloride Tablets

1. Product Introduction

Tramadol hydrochloride is a prescription centrally acting opioid analgesic used for pain severe enough to require an opioid when appropriate alternatives are inadequate. Immediate-release and sustained-release formulations are not interchangeable; their indications, dosing schedules and release properties differ.

The supplied company profile identifies Healthy Life Pharma Pvt. Ltd. as manufacturer and Healthy Inc as exporter. Specific WHO-GMP status, controlled-drug manufacturing licenses, product registrations and export authorizations must be verified before any commercial representation or shipment.

2. Product Specifications

3. Manufacturing Technology

Production requires validated controls for identity, content uniformity, cross-contamination prevention, security and traceability. Sustained-release formulations additionally require validated release-controlling excipients and manufacturing processes to minimize unintended rapid drug release. Specific HPMC grades, equipment, coatings, compression settings or 12–24-hour performance claims cannot be established from the supplied product description alone.

Controlled-medicine manufacture must occur only under the applicable manufacturing licenses and security requirements.

4. Quality Assurance

Approved quality controls typically cover identity, assay, related substances, uniformity of dosage units, dissolution, packaging integrity and stability. Immediate-release and sustained-release formulations need different, validated dissolution specifications. No universal 80%/30-minute or 90–110% release/assay limit is asserted without the relevant monograph and registered specifications. Batch release and supply require applicable quality and controlled-drug documentation.

5. Therapeutic Uses & Mechanism

Tramadol and its active metabolite act on mu-opioid receptors, while tramadol also inhibits serotonin and norepinephrine reuptake. It may be prescribed for pain severe enough to require an opioid when non-opioid options are inadequate, in accordance with the local approved indication. Extended/sustained-release formulations are generally intended for selected patients requiring ongoing pain management, not rapid treatment of occasional breakthrough pain.

Important: Tramadol is not free of serious opioid risks. Respiratory depression, misuse, dependence, overdose and death can occur even when prescribed.

6. Export & Regulatory Support

Tramadol's control status and import/export requirements vary by jurisdiction. Before B2B supply, verify the Indian manufacturing and export authorizations, destination-country import permissions, controlled-substance handling rules, product registration, licensed consignee, shipping documentation and secure chain of custody. CTD/ACTD dossiers, COPP, FSC, COA, WHO-GMP certificates and any Narcotics/CBN permits are subject to documentary verification; their availability is not guaranteed by this page.

7. Frequently Asked Questions

Q: Is tramadol an opioid?
A: Yes. It is a prescription opioid analgesic with risks of addiction, overdose and respiratory depression.

Q: Are 50 mg IR and 100/200 mg SR interchangeable?
A: No. Release profiles and prescribing requirements differ; switching requires medical supervision.

Q: Can tramadol cause seizures or serotonin syndrome?
A: Yes, particularly with susceptible patients or interacting medicines, including certain antidepressants.

Q: Are these strengths approved for export?
A: Availability and export eligibility must be checked against product registrations, manufacturing permissions and destination-country requirements.

8. Dosage & Administration

Tramadol dosing is individualized by indication, formulation, age, renal/hepatic function, other medicines and opioid exposure. There is no universal dose or schedule across IR and SR products. Follow the approved local product label and prescriber's instructions. Sustained-release tablets must not be crushed, chewed or split unless the specific approved label explicitly permits it; doing so may cause rapid release and overdose. Do not combine formulations or increase doses independently.

9. Side Effects & Precautions

Common effects include nausea, constipation, dizziness, drowsiness and vomiting. Serious risks include life-threatening respiratory depression, addiction, misuse, physical dependence and withdrawal, seizures and serotonin syndrome. Combining with alcohol, benzodiazepines, other sedatives or opioids can cause profound sedation, coma or death. MAO inhibitors and serotonergic drugs may create dangerous interactions. Risk can increase with CYP2D6/CYP3A4 drug interactions. Avoid driving until effects are known. Children and breastfeeding/pregnancy have important restrictions depending on product and jurisdiction. Seek emergency help for slow breathing, inability to wake, seizures or suspected overdose; naloxone may be used for opioid overdose while emergency care is arranged.

10. Storage Instructions

Store according to the approved product label, protected from excess heat and moisture. Keep in a secure, locked location away from children and unauthorized persons. Follow applicable controlled-medicine inventory and disposal requirements. A fixed 36-month shelf life or below-25°C storage condition must not be assumed without product-specific stability evidence.